Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Ringside’s phase 3 findings reveal the potential varegacestat has to deliver “best-in-class results in a convenient, ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

This article first appeared on GuruFocus. Merck KGaA (NYSE:MRK) is making a fresh push to rebuild its pharmaceutical firepower, and this time it is placing a multibillion-dollar bet on artificial ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have ...

Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has ...